Antibody engineering on the surface of CHO cells

Conference Dates

July 16-20, 2017


From discovery to market, antibody therapeutics are developed using several expression platforms. Antibodies are often discovered from isolated mouse or human B-cells, engineered for affinity and specificity on the surface of phage, bacteria, or yeast, and manufactured in FDA-approved mammalian cell lines. This functional engineering detour in non-mammalian platforms introduces the opportunity to adversely impact expression and stability of the final product in the mammalian production cell line. To address this shortcoming, a CHO cell display platform was developed in which the antibody therapeutic can be engineered in the CHO manufacturing cell line, streamlining the process (Fig.1). CHO cell display of an antibody Fab fragment was developed and optimized using a semi-stable episomal system capable of maintenance of a transfected plasmid for several weeks, which allows multiple rounds of flow cytometric sorting and regrowth of promising clones.

Please click Additional Files below to see the full abstract.

118.pdf (201 kB)

This document is currently not available here.